High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.

CONCLUSION: These data suggest that EREG is a potential predictive marker and therapeutic target in rectal cancer patients receiving neoadjuvant CCRT. PMID: 32408308 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32408308?dopt=Abstract

Source: Oncology - May 13, 2020 Category: Cancer & Oncology Authors: Lin CY, Hsieh PL, Chou CL, Yang CC, Lee SW, Tian YF, Shiue YL, Li WS Tags: Oncology Source Type: research

More News: Cancer | Cancer & Oncology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Rectal Cancers